Cardiff Oncology appoints Fairooz Kabbinavar as Chief Medical Officer

Cardiff Oncology, Inc.

Annual base salary $480,000, target bonus 45% of base, plus option grant.
Granted non-qualified option for 425,000 shares at $1.75/share exercise price.
Options vest over 4 years: 25% after 12 months, then monthly over 36 months.
Dr. Kabbinavar has 30+ years experience; lead investigator for bevacizumab mCRC approval trials.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fairooz Kabbinavar

Chief Medical Officer

CRDF · Cardiff Oncology, Inc.

Effective: 2023-01-30
Filed: February 2, 2023, 6:59 PM ET

On January 30, 2023, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Fairooz Kabbinavar was appointed as Chief Medical Officer at Cardiff Oncology, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On January 30, 2023, Cardiff Oncology, Inc. (the “Company”) appointed Dr. Fairooz Kabbinavar as Chief Medical Officer of the Company

View on SEC.gov

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-002037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.